B of A Securities Maintains Underperform on Integra Lifesciences, Lowers Price Target to $26
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Craig Bijou maintains an Underperform rating on Integra Lifesciences (NASDAQ:IART) and lowers the price target from $42 to $26.
May 07, 2024 | 11:35 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
B of A Securities has maintained its Underperform rating on Integra Lifesciences and reduced the price target from $42 to $26.
The reduction in price target by a significant margin suggests a bearish outlook on the stock by the analyst. This could lead to negative sentiment among investors, potentially causing a short-term decline in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100